Newsroom
Category
September 1, 2016
The UT Horizon Fund recently invested $150,000 to fund Cardiovate, a San Antonio-based startup that is using technology from two University of Texas System institutions to commercialize a medical device to treat vascular diseases by repairing blood vessels. Read the full story at The University of Texas System
September 1, 2016
Starting newly-diagnosed diabetes patients on the triple combination of metformin/pioglitazone/exenatide upfront provided better glucose control with less hypoglycemia than a standard sequential regimen, 3-year follow-up from the EDICT trial showed. Read the full story at MedPage Today
September 1, 2016
The UT Horizon Fund recently invested $150,000 to fund Cardiovate, a San Antonio-based startup that is using technology from two University of Texas System institutions to commercialize a medical device to treat vascular diseases by repairing blood vessels. Read the full story at UTSA Today
September 1, 2016
In an outcome likely to raise broad questions about aggressive prostate cancer treatment, a randomized study of 1,643 British men found that, roughly 10 years after a prostate cancer diagnosis, the vast majority of participants had survived the cancer regardless of whether they were treated with radiation, had their prostates surgically removed, or were simply […]
September 1, 2016
A first-time event, known as Stand Down for Homeless Veterans, was announced this week and plans are set to help address the needs of nearly 300 people in the four-hour service oriented session that begins at 9 a.m. and concludes at 1 p.m. on Sept. 20. Read the full story at the Laredo Morning Times
September 1, 2016
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced the publication of positive results from a Phase 2b study of vadadustat, a once-daily oral HIF stabilizer, in development for the treatment of anemia related to chronic kidney disease (CKD). Read the full story at Street Insider